Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE AND TENOFOVIR ALAFENAMIDE versus EMTRIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE AND TENOFOVIR ALAFENAMIDE versus EMTRIVA.
EMTRICITABINE AND TENOFOVIR ALAFENAMIDE vs EMTRIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that is phosphorylated to emtricitabine triphosphate, which competes with the natural substrate deoxycytidine-5'-triphosphate and incorporates into viral DNA, causing chain termination. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) that is converted to tenofovir diphosphate, which inhibits HIV-1 reverse transcriptase by competing with the natural substrate deoxyadenosine-5'-triphosphate and incorporating into DNA, leading to chain termination.
Nucleoside reverse transcriptase inhibitor; emtricitabine is phosphorylated to emtricitabine 5'-triphosphate which competes with deoxycytidine 5'-triphosphate for incorporation into viral DNA, resulting in chain termination.
One tablet (200 mg emtricitabine / 25 mg tenofovir alafenamide) orally once daily with food.
Emtricitabine 200 mg orally once daily.
None Documented
None Documented
Emtricitabine: terminal half-life ~10 hours (clinical context: supports once-daily dosing). Tenofovir alafenamide: terminal half-life ~0.5 hours (prodrug), but active tenofovir diphosphate intracellular half-life >60 hours in PBMCs (clinical context: supports once-daily dosing due to long intracellular persistence).
Terminal elimination half-life ~10 hours (mean 10 h, range 7-14 h) in adults; prolonged in renal impairment (up to 90 h in severe impairment)
Emtricitabine: primarily renal (86% unchanged) via glomerular filtration and active tubular secretion. Tenofovir alafenamide: metabolism to tenofovir, then renal (70-80% unchanged) via glomerular filtration and active tubular secretion; <1% fecal.
Renal excretion of unchanged drug (~86%) by glomerular filtration and active tubular secretion; fecal excretion (<1%)
Category A/B
Category C
NRTI
Antiretroviral, NRTI